ReviewNature reviews. Disease primers2019
Kaposi sarcoma.
Review in Nature reviews. Disease primers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 414 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
414 citing papers in PubMed, 4 syntheses or guidelines pooled it, 662 citations in OpenAlex.
- Is Kaposi sarcoma a novel comorbidity of cutaneous lymphoma? A systematic review of the literature.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2025Pooled it
- Global research landscape of HIV and Kaposi's sarcoma: a visualized bibliometric analysis.Frontiers in microbiology · 2025Pooled it
- Is human herpesvirus 8 infection more common in men than in women? an updated meta-analysis.BMC infectious diseases · 2024Pooled it
- Liposomal DoxorubicinCurrent drug delivery · 2024Pooled it
- Serum Biomarkers in Advanced-Stage AIDS-Associated Kaposi Sarcoma in Resource Limited Settings.Journal of acquired immune deficiency syndromes (1999) · 2026Trial
- Cytokine biomarkers and their relationship to symptoms and quality of life in people with HIV-associated Kaposi sarcoma.HIV medicine · 2025Trial
- Valganciclovir modulates the tumor necrosis factor axis molecules expression and CD4+ T-cell subsets in disseminated Kaposi Sarcoma patients.Clinical and experimental immunology · 2024Trial
- KSHV vIRF3-PKM2 interaction induces SMAD5 acetylation, promoting Kaposi's sarcoma progression.Experimental & molecular medicine · 2026Article
- Conserved assembly architecture of the essential herpesvirus packaging accessory factor.PLoS pathogens · 2026Article
- Pan-gammaherpesvirus control via a broadly neutralising gB antibody.Clinical and translational medicine · 2026Article
- Article
- Article
- Metabolomic Analysis of Lytic KSHV Infection: Induced Host Nucleotide Metabolism Is Required for Infectious Virus Production.Viruses · 2026Article
- In-depth characterisation of the tumour microenvironment reveals HHV-8-dependent immune regulation in HIV-associated and classic Kaposi sarcoma.British journal of cancer · 2026Article
- Demographic Characteristics, Clinical Features, and Treatment Patterns of Classic and AIDS-Related Kaposi Sarcoma: A Multicenter Real-World Study from Turkey.Medicina (Kaunas, Lithuania) · 2026Article
- Kaposi sarcoma in the era of immunodeficiency: challenges and opportunities for treatment and prevention.Annals of medicine and surgery (2012) · 2026Article
- Article
- Immunological Determinants of Oncogenic Virus-Driven Cancers in Africa: Mechanisms, Co-Infections and Public Health Challenges.Pathogens (Basel, Switzerland) · 2026Review
- Beyond the Skin: Gastrointestinal Bleeding as a First Sign of Duodenal Kaposi Sarcoma.ACG case reports journal · 2026Article
- HIV Infection and Opioid Treatment Enable the Engraftment of Kaposi Sarcoma-Like Tumors Into Immunocompetent Mice.Journal of medical virology · 2026Article
354 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 5 institutions in 2 countries.
Funding
Abstract
Kaposi sarcoma (KS) gained public attention as an AIDS-defining malignancy; its appearance on the skin was a highly stigmatizing sign of HIV infection during the height of the AIDS epidemic. The widespread introduction of effective antiretrovirals to control HIV by restoring immunocompetence reduced the prevalence of AIDS-related KS, although KS does occur in individuals with well-controlled HIV infection. KS also presents in individuals without HIV infection in older men (classic KS), in sub-Saharan Africa (endemic KS) and in transplant recipients (iatrogenic KS). The aetiologic agent of KS is KS herpesvirus (KSHV; also known as human herpesvirus-8), and viral proteins can induce KS-associated cellular changes that enable the virus to evade the host immune system and allow the infected cell to survive and proliferate despite viral infection. Currently, most cases of KS occur in sub-Saharan Africa, where KSHV infection is prevalent owing to transmission by saliva in childhood compounded by the ongoing AIDS epidemic. Treatment for early AIDS-related KS in previously untreated patients should start with the control of HIV with antiretrovirals, which frequently results in KS regression. In advanced-stage KS, chemotherapy with pegylated liposomal doxorubicin or paclitaxel is the most common treatment, although it is seldom curative. In sub-Saharan Africa, KS continues to have a poor prognosis. Newer treatments for KS based on the mechanisms of its pathogenesis are being explored.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.